Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisal guidance for migraine:
- Atogepant for preventing migraine (2024) NICE technology appraisal guidance 973
- Rimegepant for treating migraine (2023) NICE technology appraisal guidance 919
- Rimegepant for preventing migraine (2023) NICE technology appraisal guidance 906
- Eptinezumab for preventing migraine (2023) NICE technology appraisal guidance 871
- Fremanezumab for preventing migraine (2022) NICE technology appraisal guidance 764
- Erenumab for preventing migraine (2021) NICE technology appraisal guidance 682
- Galcanezumab for preventing migraine (2020) NICE technology appraisal guidance 659
- Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (2012) NICE technology appraisal guidance 260
Using the resource impact template
NICE has also produced a video on instructions for using the migraine resource impact template.
This page was last updated: